Cargando…

Phosphodiesterase Type 5 Inhibitors and COVID-19: Are They Useful In Disease Management?

Detalles Bibliográficos
Autor principal:	Mondaini, Nicola
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Korean Society for Sexual Medicine and Andrology 2020
Materias:	Editorial
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7308240/ https://www.ncbi.nlm.nih.gov/pubmed/32573126 http://dx.doi.org/10.5534/wjmh.200089

Ejemplares similares

Evolution of Phosphodiesterase-5 Inhibitors
por: Moon, Du Geon
Publicado: (2015)

COVID-19 and Phosphodiesterase Enzyme Type 5 Inhibitors
por: Al-Kuraishy, Hayder M., et al.
Publicado: (2020)

Phosphodiesterase-5 inhibitors for colon cancer chemoprevention
por: Islam, Bianca N., et al.
Publicado: (2018)

Phosphodiesterase type 5 inhibitors after left ventricular assist device: no free lunch?
por: Grandin, E. Wilson, et al.
Publicado: (2021)

Phosphodiesterase-5 inhibitors: Emerging nephroprotective drugs
por: Abassi, Zaid, et al.
Publicado: (2015)

Effect of Phosphodiesterase Inhibitor on Diabetic Nephropathy
por: Kang, Shin-Wook
Publicado: (2012)

Phosphodiesterase type 5 inhibitors: Irrational use in Saudi Arabia
por: Alshahrani, Saad, et al.
Publicado: (2016)

Peyronie's Disease: Evolving Surgical Management and the Role of Phosphodiesterase 5 Inhibitors
por: Al-Shaiji, Tariq F., et al.
Publicado: (2009)

AB030. Evolution of phosphodiesterase type 5 inhibitors
por: Moon, Du Geon
Publicado: (2016)

Determination of Phosphodiesterase Type-5 Inhibitors (PDE-5) in Dietary Supplements
por: Gheorghiu, Oana Ramona Cătălina, et al.
Publicado: (2023)

Are phosphodiesterase Type 5 inhibitors potential therapies for Alzheimer’s disease and related dementias?
por: Newby, Danielle
Publicado: (2022)

Phosphodiesterase Type 5 Inhibitors and sudden sensorineural hearing loss
por: Barreto, Monique Antunes de Souza Chelminski, et al.
Publicado: (2015)

Repurposing phosphodiesterase-5 inhibitors as chemoadjuvants
por: Tiwari, Amit K., et al.
Publicado: (2013)

The role of phosphodiesterase inhibitors in the management of pulmonary vascular diseases
por: Butrous, Ghazwan
Publicado: (2014)

Combination phosphodiesterase type 4 inhibitor and phosphodiesterase type 5 inhibitor treatment reduces non-voiding contraction in a rat model of overactive bladder
por: Balog, Brian M., et al.
Publicado: (2019)

Phosphodiesterase-5 inhibitors in management of pulmonary hypertension: safety, tolerability, and efficacy
por: Buckley, Mitchell S, et al.
Publicado: (2010)

Erectile dysfunction and heart failure: the role of phosphodiesterase type 5 inhibitors
por: Al-Ameri, H, et al.
Publicado: (2009)

Counterfeit phosphodiesterase type 5 inhibitors pose significant safety risks
por: Jackson, G, et al.
Publicado: (2010)

Chronic Low Dosing of Phosphodiesterase Type 5 Inhibitor for Erectile Dysfunction
por: Sung, Hyun Hwan, et al.
Publicado: (2012)

Phosphodiesterase type 5 inhibitors: back and forward from cardiac indications
por: Corinaldesi, C., et al.
Publicado: (2015)

Revisiting the halogen bonding between phosphodiesterase type 5 and its inhibitors
por: Jedwabny, Wiktoria, et al.
Publicado: (2019)

Phosphodiesterase Inhibitors: Could They Be Beneficial for the Treatment of COVID-19?
por: Giorgi, Mauro, et al.
Publicado: (2020)

Advantages of Phosphodiesterase Type 5 Inhibitors in the Management of Glucose Metabolism Disorders: A Clinical and Translational Issue
por: Antinozzi, Cristina, et al.
Publicado: (2020)

Phosphodiesterase-5 inhibitors and the heart: compound cardioprotection?
por: Hutchings, David Charles, et al.
Publicado: (2018)

The Effect of Phosphodiesterase-type 5 Inhibitors on Erectile Function: An Overview of Systematic Reviews
por: Pyrgidis, Nikolaos, et al.
Publicado: (2021)

Phosphodiesterase Type 5 Inhibitors and Visual Side Effects: A Narrative Review
por: Barroso, Francisco, et al.
Publicado: (2021)

Use of phosphodiesterase type 5 inhibitors and risk of melanoma: a meta-analysis of observational studies
por: Han, Xinming, et al.
Publicado: (2018)

Phosphodiesterase-5 Inhibitors as Therapeutics for Cardiovascular Diseases: A Brief Review
por: Corbic, Milena, et al.
Publicado: (2023)

Phosphodiesterase type-5 inhibitor use in type 2 diabetes is associated with a reduction in all-cause mortality
por: Anderson, Simon G, et al.
Publicado: (2016)

The Wonders of Phosphodiesterase-5 Inhibitors: A Majestic History
por: Elhwuegi, AS
Publicado: (2016)

The first‐generation phosphodiesterase 5 inhibitors and their pharmacokinetic issue
por: Zucchi, A., et al.
Publicado: (2019)

Efficacy of phosphodiesterase type 5 inhibitors in univentricular congenital heart disease: the SV‐INHIBITION study design
por: Amedro, Pascal, et al.
Publicado: (2020)

Any possible role of phosphodiesterase type 5 inhibitors in the treatment of severe COVID19 infections? A lesson from urology
por: Dal Moro, Fabrizio, et al.
Publicado: (2020)

Immunohistochemical (Ki-67) study of endometrial maturation in mice after use of phosphodiesterase type 5 inhibitor
por: Rashidi, Bahman, et al.
Publicado: (2015)

Upregulation of Phosphodiesterase type 5 in the Hyperplastic Prostate
por: Zhang, Wenhao, et al.
Publicado: (2015)

Phosphodiesterase type 5 and cancers: progress and challenges
por: Barone, Ines, et al.
Publicado: (2017)

Effects of phosphodiesterase type 5 inhibitors on choroid and ocular vasculature: a literature review
por: da Cruz, Natasha Ferreira Santos, et al.
Publicado: (2020)

Usage and perceptions of phosphodiesterase type 5 inhibitors among the male partners of infertile couples
por: Song, Seung-Hun, et al.
Publicado: (2016)

Phosphodiesterase type 5 inhibitors usage and prostate cancer: a match-paired analysis
por: Machen, G. Luke, et al.
Publicado: (2017)

Phosphodiesterase Type 5 Inhibitors Greatly Affect Physicochemical Properties of Model Lipid Membranes
por: Zakharova, Anastasiia A., et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_lqb005admn2629qq0r45mo9hvi